antibody
(2)
Russell Beckerman
Russell Beckerman is a biotech entrepreneur and Co-Founder & CEO of Overture Therapeutics, a Cambridge-based company engineering precision antibody medicines targeting obesity and metabolic dysfunction. He previously co-founded 82VS, a venture studio embedded within Alloy Therapeutics that has launched nine drug companies since 2020. His work sits at the intersection of cutting-edge antibody biology, company creation, and the conviction that the next generation of obesity drugs will be antibodies - not peptides.
Bryan Faust
Bryan Faust, PhD is an Investment Partner on the Bio + Health team at Andreessen Horowitz (a16z), where he backs seed and Series A companies at the intersection of biology and technology. A trained biophysicist with a PhD from UCSF, he published research in Nature, Science, and Cell before pivoting to venture—studying antibody-protein interactions, GPCR signaling, and COVID-19 nanobodies along the way. At a16z he has co-led investments in Stipple Bio, Tessera Labs, Gate Bioscience, and Formation Bio, and writes widely on AI in life sciences, biotech financing, and the coming era of programmable medicine. When he's not reading pitch decks, he's surfing, roasting coffee, or hunting down the perfect tacos al pastor.